Drug Development

Stubborn Actelion CEO Clozel spurs shift in buyout talks, but J&J counters with a raised bid — reports

Jean-Paul Clozel

Jean-Paul Clozel, Actelion

Actelion was never going to be an eager partner in any takeover attempt. The Swiss biotech’s CEO, Jean-Paul Clozel, has stubbornly resisted earlier attempts to force a change in ownership. And now The Financial Times is reporting that his stolid attitude spurred J&J to start investigating a possible tie-up rather than an outright buyout.

The FT team reports that Clozel was predictably resistant to J&J’s overture to acquire the company, which boosted Actelion’s market cap to about $20 billion. Its shares dropped, though, after the FT’s report that J&J may pursue the more complicated approach of buying into the company in a move that would still leave Actelion acting as an independent entity.

Then, later in the morning, Actelion’s shares shot up 10% after Bloomberg reported that Actelion had turned down a $25 billion offer and Reuters added a piece stating that J&J had boosted its offer.

Both companies have acknowledged that talks are underway, but are staying tight-lipped about any of the terms being discussed.

The FT cited sources close to the buyout talks.

The follow-up reports would indicate that J&J clearly wants to avoid a more complicated deal when it can easily afford to complete a simple acquisition.

Roche, where Clozel worked before spinning out Actelion as a separate company, has also been frequently cited as a possible bidder for the Swiss company. But Clozel and his team have stayed focused on building sales with two new therapies, vowing to take Actelion to a whole new level — on their own.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->